Hepatitis C and human immunodeficiency virus coinfection and antiretroviral multitherapies;La co-infection par les virus de l'hepatite C et de l'immunodeficience humaine a l'ere des multitherapies antiretrovirales

Gastroenterologie Clinique et Biologique

Volumn 23, Issue 8-9, 1999, Pages 878-881

  Zylberberg, Hervé ^a   Pol, Stanislas ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; RIBAVIRIN; STAVUDINE; ZIDOVUDINE;

DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG EFFICACY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; NOTE; PATHOPHYSIOLOGY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 0032881105     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (36)

1. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996;23:1117-25.
2. re partie : foie, VIH et virus des hépatites B, C et D. Gastroenterol Clin Biol 1996;20:269-80.
3. Quan CM, Krajden M, Grigoriew GA, Salit IE. Hepatitis C virus infection in malades infected with the human immunodeficiency virus. Clin Infect Dis 1993;17:117-9.
4. Dorruci M, Pezzoti M, Phillips AN, Lepri AC, Rezza G. Co-infection of hepatitis C virus with immunodeficiency virus and progression to AIDS. J Infect Dis 1995;172:1503-8.
5. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardière R, Aho LS, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected malades ? AIDS 1998;12:381-8.
6. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus and immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997;175:164-8.
7. Chamot E, Hirschel B, Wintsch J, Robert CF, Gabriel V, Deglon JJ, et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS 1990;4:1275-7.
8. Giovanninni M, Tagger A, Ribero ML, Zuccotti G, Pogliani L, Grossi A, et al. Maternal-infant transmission of hepatitis C virus and HIV infections : a possible interaction. Lancet 1990;335:1166.
9. Pol S, Lamorthe B, Trinh Thi N, Thiers V, Carnot F, Zylberberg H, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998;28:945-50.
10. Soto B, Sanchez-Quijano A, Rodrigo L, Del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterraly-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
11. Pol S, Fontaine H, Carnot F, Zylberberg H, Berthelot P, Brechot C, et al. The natural history of parenterally-acquired chronic hepatitis C. J Hepatol 1998;29:12-20.
12. Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, et al. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected malades. Clin Infect Dis 1996;23:585-91.
13. Geffray L, Rosenthal E, Perronne C, Cacoub P, Raguin G, Veyssier P, et al. (résumé). Rev Med Interne 1997;18:78S.
14. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-31.
15. Lipsky James J. Antiretroviral drugs for AIDS. Lancet 1996;348: 800-3.
16. Serfaty L, Aumaitre H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
17. Gerber MA. Pathobiologic effects of hepatitis C. J Hepatol 1995;22:83-6.
18. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997;158:1473-81.
19. Vento S, Cainelli F, Mirandola F, Cosco L, Di Perri G, Solbiati M, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996;347:92-3.
20. Ballardini G, Groff P, Pontisso P, Giostra F, Fransesconi R, Lenzi M, et al. Hepatitis C virus genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C and intercellular adhesion molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in malades with chronic hepatitis C. J Clin Invest 1995;95:2067-75.
21. Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus-associated cirrhosis in HIV coinfected patient in relation to antiretroviral tritherapy. Clin Infect Dis 1998;27:1255-8.
22. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected malades on antiretroviral combination therapy. AIDS 1998;12:116-7.
23. th World AIDS conference Geneve 1998. Abstract 22243.
24. Zylberberg H, Carnot F, Mamzer MF, Blancho G, Pol S. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997;63:158-60.
25. Rutchmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus protease inhibitors on hepatitis C viremia in malades coinfected with HIV. J Infect Dis 1998;177:783-5.
26. Zylberberg H, Chaix ML, Rabian C, Rouzioux C, Brechot C, Viard JP, et al. Anti-HIV tritherapy does not modify HCV replication in coinfected subjects. Clin Infect Dis 1998;26:1104-6.
27. Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS malades treated by indinavir. Lancet 1997 349:924-5.
28. Carr A, Cooper D. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997;340:995-6.
29. Arribas JR, Ibanez C, Ruiz-AntoranB, Pena JM, Esteban-Calvo C, Frias J, et al. Acute hepatitis in HIV-infected malades during ritonavir treatment.AIDS 1998;12:1722-4.
30. John M, Flexman J, French MAH. Hepatitis C virus associated hepatitis following treatment of HIV-infected malades with HIV protease inhibitors : an immune restoration disease ? AIDS 1998;12:2289-93.
31. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;252:1426-32.
32. Mc Hutchinson JG, Gordon SC, Schiff ER, Schiff ER, Schifman ML, Lee WL, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
33. Davis GL, Esteban-Mur R, Rustgi V, Hoefo J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
34. Spanish Ribavirin Trial Group. Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. Lancet 1991;338:6-9.
35. Vogt MW, Hartson KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-9.
36. Zylberberg H, Landau A, Chaix ML, Fontaine H, Pialoux G, Brechot C, et al. Ribavirin does not modify HIV replication in HCV-HIV coinfected subjects under antiretroviral regimen (abstract) Hepatology 1998;28:479A.